{"drugs":["Ragwitek","Short Ragweed Pollen Allergen Extract"],"mono":{"0":{"id":"930941-s-0","title":"Generic Names","mono":"Short Ragweed Pollen Allergen Extract"},"1":{"id":"930941-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930941-s-1-4","title":"Adult Dosing","mono":"<ul><li>administer first dose in a healthcare setting under supervision of a physician experienced with severe allergic reactions; monitor patient closely for 30 minutes<\/li><li><b>Allergic rhinitis due to weed pollens - Grass desensitization therapy:<\/b> 1 tablet (12 Amb a 1-units) SL once daily, starting at least 3 months prior to allergy season and continuing through the season<\/li><\/ul>"},"1":{"id":"930941-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"930941-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Allergic rhinitis due to weed pollens - Grass desensitization therapy<br\/>"}}},"2":{"id":"930941-s-2","title":"Black Box Warning","mono":"<b>Sublingual (Tablet)<\/b><br\/>Short ragweed (Ambrosia artemisiifolia) pollen extract can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal restriction. Do not administer short ragweed pollen extract to patients with severe, unstable or uncontrolled asthma. Observe patients in the office for at least 30 minutes following the initial dose. Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. Short ragweed pollen extract may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction or for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.<br\/>"},"3":{"id":"930941-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930941-s-3-9","title":"Contraindications","mono":"<ul><li>asthma, severe, unstable, or uncontrolled<\/li><li>eosinophilic esophagitis, history<\/li><li>hypersensitivity to any inactive component (gelatin, mannitol, sodium hydroxide) of the product<\/li><li>local reaction, severe, from sublingual allergen immunotherapy, history<\/li><li>systemic allergic reactions, severe, history<\/li><\/ul>"},{"id":"930941-s-3-10","title":"Precautions","mono":"<ul><li>severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be life-threatening may occur; consider discontinuation for escalating or persistent local reactions in the mouth or throat<\/li><li>systemic allergic reactions, life-threatening, such as anaphylaxis may occur; administer initial dose in a healthcare setting and observe patient for at least 30 minutes after dose; prescribe auto-injectable epinephrine for home use<\/li><li>acute asthma exacerbation; withhold therapy during exacerbation; reevaluate patient with recurrent asthma exacerbation and consider discontinuation<\/li><li>compromised lung function (chronic or acute), unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension; may reduce ability to survive a serious allergic reaction or increase risk of adverse reactions with epinephrine administration<\/li><li>concomitant beta-adrenergic blockers; may be unresponsive to usual doses of epinephrine used to treat serious systemic reactions, including anaphylaxis<\/li><li>concomitant allergen immunotherapy; may increase likelihood of local or systemic adverse reactions to either subQ or SL allergen immunotherapy<\/li><li>eosinophilic esophagitis has been reported with SL immunotherapy; discontinue in presence of severe or persistent gastroesophageal symptoms, including dysphagia or chest pain<\/li><li>oral inflammation (eg, oral lichen planus, mouth ulcers, thrush) or wounds (those following oral surgery or dental extraction); interrupt therapy until oral cavity completely healed<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930941-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930941-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"930941-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Edema of oral soft tissues, Mouth (6.1%), Itching, Oral (10.9%), Itching, Tongue (5.1%), Oral paresthesia (10%)<\/li><li><b>Otic:<\/b>Itching, Ear (10.4%)<\/li><li><b>Respiratory:<\/b>Throat irritation (16.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Edema of the tongue (1.3% to 2.9%), Eosinophilic esophagitis<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Respiratory:<\/b>Asthma<\/li><\/ul>"},"6":{"id":"930941-s-6","title":"Drug Name Info","sub":{"0":{"id":"930941-s-6-17","title":"US Trade Names","mono":"Ragwitek<br\/>"},"2":{"id":"930941-s-6-19","title":"Class","mono":"Immunological Agent<br\/>"},"3":{"id":"930941-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930941-s-7","title":"Mechanism Of Action","mono":"The exact mechanism of allergen immunotherapy is unknown.<br\/>"},"9":{"id":"930941-s-9","title":"Administration","mono":"<b>Sublingual<\/b><br\/><ul><li>SL administration only<\/li><li>administer first dose under supervision of a physician with experience in diagnosis and treatment of severe allergic reactions; observe patient for at least 30 minutes<\/li><li>remove from blister pack just prior to dosing; place tablet under tongue for at least 1 minute (until complete dissolution) and then swallow<\/li><li>wash hands after handling tablet; avoid food or beverages for 5 minutes after administration<\/li><li>missed dose: up to 7 days were allowed in clinical trials<\/li><\/ul>"},"10":{"id":"930941-s-10","title":"Monitoring","mono":"<ul><li>improvement in symptoms of allergic rhinitis or decreased use of rescue medication indicate efficacy<\/li><li>signs or symptoms of severe allergic reaction; observe for at least 30 minutes after initial dose<\/li><li>escalating or persistent local reactions in mouth and throat; consider discontinuation of treatment<\/li><li>recurrent asthma exacerbations; reevaluate and consider discontinuation of treatment<\/li><\/ul>"},"13":{"id":"930941-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient about the symptoms of a severe allergic reaction and the proper use of emergency self-injection epinephrine.<\/li><li>Advise asthma patient to immediately report difficulty breathing or worsening of asthma symptoms.<\/li><li>Side effects may include throat irritation, mouth edema, or pruritus of ears, mouth, or tongue.<\/li><li>Warn patient to report severe or persistent symptoms of esophagitis or oral edema.<\/li><li>Advise patient to report persistent or worsening adverse effects of the mouth or throat.<\/li><li>Instruct patient to place tablet under tongue and do not swallow until completely dissolved (at least one minute).<\/li><li>Advise patient to avoid taking drug with food or beverage. Do not consume food or beverage for at least 5 minutes after dissolution.<\/li><li>Tell patient to wash hands immediately following administration.<\/li><\/ul>"}}}